Information Provided By: 
Fly News Breaks for October 4, 2019
SRPT
Oct 4, 2019 | 12:27 EDT
H.C. Wainwright analyst Debjit Chattopadhyay maintained a Buy rating and $160 price target on Sarepta Therapeutics, stating in a note titled 'Muscular Dystrophy Toolbox Delivers Compelling Reads Across Programs' that "functional and biochemical improvements across SRP-9003 and SRP-9001 are suggestive of a gene therapy clinical benefit." The analyst added that the clinical benefit of canonical gene therapy programs is "becoming more incontrovertible."
News For SRPT From the Last 2 Days
There are no results for your query SRPT
